Advertisement

American Journal of Cardiovascular Drugs

, Volume 18, Issue 2, pp 93–102 | Cite as

The Effect of Endothelin Receptor Antagonists in Patients with Eisenmenger Syndrome: A Systematic Review

  • Abdelrahman Elshafay
  • Duy Hieu Truong
  • Mohamed M. AboElnas
  • Hossam Idrees
  • Hatem G. Metwali
  • Nguyen Lam Vuong
  • Omar Ahmed Saad
  • Kenji Hirayama
  • Nguyen Tien Huy
Systematic Review
  • 228 Downloads

Abstract

Introduction

The efficacy of endothelin receptor antagonists (ERAs) in the management of Eisenmenger syndrome (ES) remains controversial. The aim of this study is to systemically review the safety and effects of ERAs in improving the quality of life and basic cardiac functions of these patients.

Methods

Twelve databases were searched, including PubMed, Web of Science, Scopus, Virtual Health Library, World Health Organization (WHO) Global Health Library, Google Scholar, POPLINE, Systems for Information of Grey Literature in Europe, New York Academy of Medicine, ClinicalTrials.gov, metaRegister of Controlled Trials and the WHO International Clinical Trials Registry Platform, through August 2016. We included randomized clinical trials addressing the effect of ERAs on cardiac functions in patients with ES. The quality of studies was assessed using the Cochrane Collaboration tool.

Results

We included two trials represented by four papers, of which three papers reported the efficacy of bosentan against placebo and one paper reported the results of a combination of bosentan and sildenafil versus placebo and bosentan. One trial showed a significant effect of bosentan treatment over placebo on indexed pulmonary vascular resistance and mean pulmonary artery pressure, but a non-significant increase in 6-min walk distance and a non-significant effect on systemic pulse oximetry. The other trial reported the safe but non-significant effect of combination therapy of bosentan and sildenafil compared with bosentan and placebo.

Conclusions

This study demonstrated safety and improved hemodynamic effects of bosentan in ES, with a controversial effect on exercise capacity. Further randomized controlled trials with longer follow-up duration are needed to confirm these results.

Notes

Compliance with ethical standards

Funding

This study was supported in part by a “Grant-in-Aid for Scientific Research (B)” (16H05844, 2016–2019 for Nguyen Tien Huy) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, and by the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID) (for Kenji Hirayama). The funders had no role in the study design, data collection and analysis, the preparation of the manuscript, or the decision to publish.

Conflict of interest

Abdelrahman Elshafay, Duy Hieu Truong, Mohamed M. AboElnas, Hossam Idrees, Hatem G. Metwali, Nguyen Lam Vuong, Omar Ahmed Saad, Kenji Hirayama, and Nguyen Tien Huy declare that they have no conflict of interest that might be relevant to the contents of this manuscript.

Supplementary material

40256_2017_240_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 17 kb)

References

  1. 1.
    van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58(21):2241–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Van Riel A, Schuuring M, Van Hessen I, Zwinderman A, Cozijnsen L, Reichert C, et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol. 2014;174(2):299–305.CrossRefPubMedGoogle Scholar
  3. 3.
    Simonneau G, Gatzoulis M, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25):D34–41.CrossRefPubMedGoogle Scholar
  4. 4.
    Beghetti M, Galiè N. Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;53(9):733–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Berman E, Barst R. Eisenmenger’s syndrome: current management. Progress in cardiovascular diseases. Prog Cardiovasc Dis. 2002;45(2):129–38.CrossRefPubMedGoogle Scholar
  6. 6.
    Frank D, Hanna B. Pulmonary arterial hypertension associated with congenital heart disease and Eisenmenger syndrome: current practice in pediatrics. Miner Pediatr. 2015;67(2):169.Google Scholar
  7. 7.
    Diller G, Körten M, Bauer U, Miera O, Tutarel O, Kaemmerer H, et al. Current therapy and outcome of Eisenmenger syndrome: data of the German National Register for congenital heart defects. Eur Heart J. 2016;37(18):1449–55.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Fukushima H. Update on medical treatment of patients with Eisenmenger syndrome. Int Heart J. 2015;56(Suppl:S4-7).Google Scholar
  9. 9.
    Wort S, Woods M, Warner T, Evans T, Mitchell J. Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling. Am J Respir Cell Mol Biol. 2001;25(1):104–10.CrossRefPubMedGoogle Scholar
  10. 10.
    Channick R, Simonneau G, Sitbon O, Robbins I, Frost A, Tapson V, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Gatzoulis MA, Rogers P, Li W, Harries C, Cramer D, Ward S, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol. 2005;98(1):147–51.CrossRefPubMedGoogle Scholar
  12. 12.
    Kaya MG, Lam YY, Erer B, Ayhan S, Vatankulu MA, Nurkalem Z, et al. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome. J Card Fail. 2012;18(5):379–84.CrossRefPubMedGoogle Scholar
  13. 13.
    Rubin L, Badesch D, Barst R, Galie N, Black C, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903.CrossRefPubMedGoogle Scholar
  14. 14.
    Liberati A, Altman D, Tetzlaff J, Mulrow C, Gøtzsche P, Ioannidis J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;21(339):b2700.CrossRefGoogle Scholar
  15. 15.
    Huy N, Elshafay A, Vuong N, Truong D, AboElnas M, Gamal H, et al. Safety and efficacy of endothelin receptor antagonist on cardiac function in patients with Eisenmenger syndrome a systematic review and meta-analysis of randomized clinical trials. PROSPERO 2016:CRD42016048731.Google Scholar
  16. 16.
    Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;18(343):d5928.CrossRefGoogle Scholar
  17. 17.
    Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Gatzoulis MA, Beghetti M, Galie N, Granton J, Berger RM, Lauer A, et al. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. 2008;127(1):27–32.CrossRefPubMedGoogle Scholar
  19. 19.
    Berger RM, Beghetti M, Galie N, Gatzoulis MA, Granton J, Lauer A, et al. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger’s syndrome: a subgroup analysis. Int J Cardiol. 2010;144(3):373–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. 2010;31(9):1124–31.CrossRefPubMedGoogle Scholar
  21. 21.
    Coeytaux R, Schmit K, Kraft B, Kosinski A, Mingo A, Vann L, et al. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 2014;145(5):1055–63.CrossRefPubMedGoogle Scholar
  22. 22.
    Kuntz M, Leiva-Juarez M, Luthra S. Systematic review of randomized controlled trials of endothelin receptor antagonists for pulmonary arterial hypertension. Lung. 2016;194(5):723–32.CrossRefPubMedGoogle Scholar
  23. 23.
    Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2013 (2):CD004434.Google Scholar
  24. 24.
    Hascoet S, Fournier E, Jaïs X, Le Gloan L, Dauphin C, Houeijeh A, et al. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: a French multicentre study. Arch Cardiovasc Dis. 2017.Google Scholar
  25. 25.
    Dimopoulos K, Giannakoulas G, Wort S, Gatzoulis M. Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Curr Opin Cardiol. 2008;23(6):545–54.CrossRefPubMedGoogle Scholar
  26. 26.
    Kempny A, Hjortshøj CS, Gu H, Li W, Opotowsky AR, Landzberg M, et al. Predictors of death in contemporary adult patients with Eisenmenger syndrome: a multicentre study. Circulation. 2016:CIRCULATIONAHA.116.023033.Google Scholar
  27. 27.
    Apostolopoulou SC, Rammos S, Kyriakides ZS, Webb DJ, Johnston NR, Cokkinos DV, et al. Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease. Heart. 2003;89(10):1221–6.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Rubin L, Badesch D, Barst R, Galie N, Black C, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903.CrossRefPubMedGoogle Scholar
  29. 29.
    Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease. Heart. 2005;91(11):1447–52.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Oechslin E, Mebus S, Schulze-Neick I, Niwa K, Trindade P, Eicken A, et al. The adult patient with Eisenmenger syndrome: a medical update after Dana Point part III: specific management and surgical aspects. Curr Cardiol Rev. 2010;6(4):363–72.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gupta V, Tonelli A, Krasuski R. Congenital heart disease and pulmonary hypertension. Heart Fail Clin. 2012;8(3):427–45.CrossRefPubMedGoogle Scholar
  32. 32.
    Duffels MG, Vis JC, van Loon RL, Berger RM, Hoendermis ES, van Dijk AP, et al. Down patients with Eisenmenger syndrome: is bosentan treatment an option? Int J Cardiol. 2009;134(3):378–83.CrossRefPubMedGoogle Scholar
  33. 33.
    Duffels MGJ, Berger RMF, Bresser P, de Bruin-Bon HACM, Hoendermis E, Bouma BJ, et al. Applicability of bosentan in Dutch patients with Eisenmenger syndrome preliminary results on safety and exercise capacity. Neth Heart J. 2006;14(5):165–70.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Kermeen FD, Franks C, O’Brien K, Seale H, Hall K, McNeil K, et al. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21. Heart Lung Circ. 2010;19(10):595–600.CrossRefPubMedGoogle Scholar
  35. 35.
    D’Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, et al. Bosentan–Sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. 2012;155(3):378–82.CrossRefPubMedGoogle Scholar
  36. 36.
    Douwes J, Roofthooft M, Van Loon R, Ploegstra M, Bartelds B, Hillege H, et al. Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre. Heart. 2014;100(3):224–30.CrossRefPubMedGoogle Scholar
  37. 37.
    Amedro P, Basquin A, Gressin V, Clerson P, Jais X, Thambo J-B, et al. Health-related quality of life of patients with pulmonary arterial hypertension associated with CHD: the multicentre cross-sectional ACHILLE study. Cardiology in the Young. 2016:1–10.Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Faculty of MedicineAl-Azhar UniversityCairoEgypt
  2. 2.Quang Binh pharmaceutical joint-stock companyQuang BinhVietnam
  3. 3.Faculty of MedicineCairo UniversityCairoEgypt
  4. 4.Faculty of MedicineAssiut UniversityAssiutEgypt
  5. 5.Faculty of PharmacyAssiut UniversityAssiutEgypt
  6. 6.Department of Cardiovascular SurgeryUniversity Medical CenterHo Chi Minh CityVietnam
  7. 7.Department of Medical statistic and Informatics, Faculty of Public HealthUniversity of Medicine and PharmacyHo Chi Minh CityVietnam
  8. 8.Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Graduate School of Biomedical SciencesNagasaki UniversityNagasakiJapan
  9. 9.Evidence Based Medicine Research Group and Faculty of Applied SciencesTon Duc Thang UniversityHo Chi Minh CityVietnam
  10. 10.Department of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), Leading Graduate School Program, and Graduate School of Biomedical SciencesNagasaki UniversityNagasakiJapan

Personalised recommendations